The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
however there are no published double blinded randomized controlled trials for its use in the treatment of Koba 19 it is possible that it may be used to treat symptomatic patients and may decrease the length of time the virus remains in the respiratory tract thus limiting community spread however more data is needed and this is based off of the very limited data that has been published which is not super high quality data
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.